Antiviral drugs under development in the SCORE consortium update 2022: 

  • The antiviral drug 13b-K, a viral inhibitor of SARS-CoV-2 Mpro
  • The drug line series 06, an antiviral specific for SARS-CoV-2 (see SCORE newsletters)
  • The drug line series 08, a broad spectrum coronavirus antiviral which is further developed within the CARE consortium (see SCORE newsletters)
  • HR2 entry inhibitors for SARS-CoV-2
  • SAR405, an inhibitor of the host VPS34 (class III PI3K).
  • Suramin, a broad spectrum antiviral, is applied to SARS-CoV-2 with a new application method